This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MURRAY FRANK LLP Announces Investigation Of Pharmaceutical Product Development, Inc.

MURRAY FRANK LLP is investigating claims of breach of fiduciary duties by certain members of the board of directors of Pharmaceutical Product Development, Inc. (NYSE: PPDI) (“PPD” or the “Company”) in relation to the acquisition of the Company by private equity firms Carlyle Group (“Carlyle”) and Hellman & Friedman LLC (“Hellman & Friedman”).

On October 3, 2011, PPD announced that the Company had entered into an Agreement and Plan of Merger with Carlyle and Hellman & Friedman pursuant to an all-cash transaction under which PPD stockholders will receive $33.25 in exchange for each share of PPD common stock, an aggregate value of approximately $3.9 billion.

The investigation seeks to determine whether certain members of the board of directors breached their fiduciary duties in connection with their efforts to sell PPD to Carlyle and Hellman & Friedman at an inadequate price through an unfair process which significantly undervalues the Company.

If you are a current investor in PPD, who purchased PPDI shares before October 3, 2011, and you wish to discuss this investigation or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Bridget V. Hamill at (800) 497-8076 or (212) 682-1818, or by email at investigations@murrayfrank.com.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs